Ott: Machine learning maturity is accelerating genomics research
Gabriel Ott · a16z Podcast | On the Genomics of Disease, From Science to Business · Jan 2, 2019 · at 1:23
Gabriel Ott, co-founder and CEO of Freenome, discusses how computational biology and AI hardware differ from early 2000s genomic analysis tools.
0:00 / 0:19exact quote · 20.0s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“What's different now as opposed to what was happening in 2000 is finally the technology, the machine learning techniques, as well as the hardware supporting that has matured to a point where we don't have to try to manually figure this complicated system out by ourselves. We can do it in a computationally aided manner, which is greatly accelerating research in this field.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Gabriel Ott
Otte: Insurance payers and clinicians are blocking diagnostic innovation
“It's really the payers and some of the clinicians that are being the inhibitors to this progress.”
Ott: Dynamic DNA testing will enable detection of any disease with immune changes
“The underlying biology should theoretically enable us to detect any diseases where there is an immune change.”
Ott: Mammography Screenings Have a 50% False Positive Rate
“Breast cancer, and specifically mammography as a screening method, has a false positive rate of 50%.”
Otte: PSA tests and mammograms have false positive rates up to 75%
“In the field of cancer screening, cancer diagnostics, we're used to, like, really, really bad tests. So like PSA for prostate cancer detection, mammography for breast cancer detection, these things have false positive rates of anywhere from, ah, 50 to 75%.”